Literature DB >> 20423673

Designing T cells for cancer immunotherapy.

Leslie E Huye1, Gianpietro Dotti.   

Abstract

Adoptive transfer of T cells can enhance immune-mediated elimination of tumor cells and provides a specific, non-toxic cancer therapy. This approach has been effective in treating some hematologic and solid malignancies. In addition, the ability to genetically modify T cells to enhance their activity and persistence as well as overcome tumor immune evasion mechanisms has the potential to increase the success of these therapies in a wide range of tumors. In this review we discuss methods for gene transfer and specific modifications that have been made to T cells.

Entities:  

Mesh：

Year:  2010        PMID： 20423673      PMCID： PMC2931319     

Source DB:  PubMed          Journal:  Discov Med        ISSN： 1539-6509            Impact factor:   2.970


  33 in total

Review 1.  Design of retroviral vectors and helper cells for gene therapy.

Authors:  W S Hu; V K Pathak
Journal:  Pharmacol Rev       Date:  2000-12       Impact factor: 25.468

2.  Is retroviral gene marking too dangerous to use?

Authors:  M K Brenner; H E Heslop
Journal:  Cytotherapy       Date:  2003       Impact factor: 5.414

3.  Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.

Authors:  K Liu; S A Rosenberg
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

5.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Authors:  Catherine M Bollard; Claudia Rössig; M Julia Calonge; M Helen Huls; Hans-Joachim Wagner; Joan Massague; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Authors:  C M Rooney; C A Smith; C Y Ng; S K Loftin; J W Sixbey; Y Gan; D K Srivastava; L C Bowman; R A Krance; M K Brenner; H E Heslop
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

7.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

8.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Authors:  Concetta Quintarelli; Juan F Vera; Barbara Savoldo; Greta M P Giordano Attianese; Martin Pule; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-07-17       Impact factor: 22.113

9.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Authors:  Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307
View more
  1 in total

1.  Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies.

Authors:  Ramon Mohanlal; Yuhong Qiu; Ming Zheng; Asmae Mirkou; Kanaka Sridharan; Christopher Keir
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.